Cite
HARVARD Citation
El-Khoueiry, A. et al. (n.d.). A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D). European journal of cancer. pp. S11-. [Online].